Impact of Insulin-Treated Compared to Non-Insulin-Treated Diabetes Mellitus on Outcome of Percutaneous Coronary Intervention with Drug-Coated Balloons versus Drug-Eluting Stents in De Novo Coronary Artery Disease: The Randomized BASKET-SMALL 2 Trial.

diabetes mellitus drug-coated balloon drug-eluting stent small vessel disease target vessel revascularization

Journal

Journal of cardiovascular development and disease
ISSN: 2308-3425
Titre abrégé: J Cardiovasc Dev Dis
Pays: Switzerland
ID NLM: 101651414

Informations de publication

Date de publication:
13 Mar 2023
Historique:
received: 20 01 2023
revised: 16 02 2023
accepted: 06 03 2023
medline: 29 3 2023
entrez: 28 3 2023
pubmed: 29 3 2023
Statut: epublish

Résumé

We evaluated the outcome of PCI of de novo stenosis with drug-coated balloons (DCB) versus drug-eluting stents (DES) in patients with insulin-treated diabetes mellitus (ITDM) versus non-insulin-treated diabetes mellitus (NITDM). Patients were randomized in the BASKET-SMALL 2 trial to DCB or DES and followed over 3 years for MACE (cardiac death, non-fatal myocardial infarction [MI], and target vessel revascularization [TVR]). Outcome in the diabetic subgroup ( In NITDM patients ( DCB compared to DES for treatment of de novo coronary lesions in diabetic patients was associated with similar rates of MACE and numerically lower need for TVR both for ITDM and NITDM patients.

Sections du résumé

BACKGROUND BACKGROUND
We evaluated the outcome of PCI of de novo stenosis with drug-coated balloons (DCB) versus drug-eluting stents (DES) in patients with insulin-treated diabetes mellitus (ITDM) versus non-insulin-treated diabetes mellitus (NITDM).
METHODS METHODS
Patients were randomized in the BASKET-SMALL 2 trial to DCB or DES and followed over 3 years for MACE (cardiac death, non-fatal myocardial infarction [MI], and target vessel revascularization [TVR]). Outcome in the diabetic subgroup (
RESULTS RESULTS
In NITDM patients (
CONCLUSIONS CONCLUSIONS
DCB compared to DES for treatment of de novo coronary lesions in diabetic patients was associated with similar rates of MACE and numerically lower need for TVR both for ITDM and NITDM patients.

Identifiants

pubmed: 36975883
pii: jcdd10030119
doi: 10.3390/jcdd10030119
pmc: PMC10057565
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Clin Res Cardiol. 2015 Mar;104(3):217-25
pubmed: 25349065
Am J Cardiol. 2010 Nov 1;106(9):1201-7
pubmed: 21029813
Clin Cardiol. 2018 May;41(5):569-575
pubmed: 29527709
J Interv Cardiol. 2016 Oct;29(5):454-460
pubmed: 27578540
JACC Cardiovasc Interv. 2018 Dec 10;11(23):2381-2392
pubmed: 30522667
JACC Cardiovasc Interv. 2015 Jul;8(8):1132-1134
pubmed: 26205451
JACC Cardiovasc Interv. 2020 Jun 22;13(12):1391-1402
pubmed: 32473887
Hellenic J Cardiol. 2011 Jan-Feb;52(1):15-22
pubmed: 21292603
N Engl J Med. 1987 May 28;316(22):1371-5
pubmed: 3574413
J Am Coll Cardiol. 2014 Sep 23;64(12):1189-97
pubmed: 25236509
Catheter Cardiovasc Interv. 2020 Aug;96(2):298-308
pubmed: 32162781
Cardiovasc Revasc Med. 2020 Jan;21(1):78-85
pubmed: 30956042
JACC Cardiovasc Interv. 2020 Dec 28;13(24):2840-2849
pubmed: 33248978
JACC Cardiovasc Interv. 2013 Apr;6(4):357-68
pubmed: 23523454
J Am Coll Cardiol. 1998 Sep;32(3):584-9
pubmed: 9741497
Am J Cardiol. 2018 Jun 15;121(12):1505-1511
pubmed: 29751955
J Diabetes Res. 2021 Jul 29;2021:5495219
pubmed: 34368364
J Am Coll Cardiol. 2011 Dec 6;58(24):e44-122
pubmed: 22070834
Cardiovasc Diabetol. 2015 Oct 07;14:135
pubmed: 26446829
JACC Cardiovasc Interv. 2021 Aug 23;14(16):1789-1798
pubmed: 34412797
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
Interv Cardiol. 2019 Nov 18;14(3):131-136
pubmed: 31867057
Lancet. 2018 Sep 8;392(10150):849-856
pubmed: 30170854
Lancet. 2020 Nov 7;396(10261):1504-1510
pubmed: 33091360
Korean Circ J. 2022 Jun;52(6):444-454
pubmed: 35491479
J Am Coll Cardiol. 2012 Oct 16;60(16):1581-98
pubmed: 22958960
J Am Coll Cardiol. 2002 Aug 7;40(3):410-7
pubmed: 12142104
Arch Cardiovasc Dis. 2017 Apr;110(4):259-272
pubmed: 28274589
Int J Cardiol. 2017 Jan 1;226:60-64
pubmed: 27788391

Auteurs

Julia Seeger (J)

Medical Campus Lake Constance, Department of Cardiology and Intensive Care, 88048 Friedrichshafen, Germany.

Jochen Wöhrle (J)

Medical Campus Lake Constance, Department of Cardiology and Intensive Care, 88048 Friedrichshafen, Germany.

Bruno Scheller (B)

Clinical and Experimental Interventional Cardiology, University of Saarland, 66421 Homburg, Germany.

Ahmed Farah (A)

Knappschaftskrankenhaus, Klinikum Westfalen, 44143 Dortmund, Germany.

Marc-Alexander Ohlow (MA)

SRH Wald-Klinikum Gera, 07548 Gera, Germany.

Norman Mangner (N)

Herzzentrum Dresden, Department of Internal Medicine and Cardiology, Technische Universität Dresden, 01062 Dresden, Germany.

Sven Möbius-Winkler (S)

Department of Cardiology, University Hospital Jena, 07747 Jena, Germany.

Daniel Weilenmann (D)

Cantonal Hospital St Gallen, 9007 St. Gallen, Switzerland.

Georg Stachel (G)

Heart Center Leipzig, University Hospital, 04289 Leipzig, Germany.

Gregor Leibundgut (G)

Cantonal Hospital Baselland, 4410 Liestal, Switzerland.

Peter Rickenbacher (P)

University Hospital Basel, University of Basel, 4001 Basel, Switzerland.

Marco Cattaneo (M)

University Hospital Basel, University of Basel, 4001 Basel, Switzerland.

Nicole Gilgen (N)

University Hospital Basel, University of Basel, 4001 Basel, Switzerland.

Christoph Kaiser (C)

University Hospital Basel, University of Basel, 4001 Basel, Switzerland.

Raban Jeger (R)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, 4031 Basel, Switzerland.
Department of Cardiology, Triemli Hospital Zurich, 8063 Zurich, Switzerland.

Classifications MeSH